top of page
  • Glenn Hearson

Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia

Updated: Jun 10, 2019


Infant 13-valent pneumococcal conjugate vaccination (PCV13) was introduced to the UK in 2010. Its impact on serotypes implicated in adult non-bacteraemic pneumococcal pneumonia is not known. Beginning in 2008, a 5-year prospective cohort study of adults admitted to hospital with community-acquired pneumonia (CAP) was conducted.


Investigator: Lin Wei Shen

This research was published in the European Respiratory Journal in June 2015:

5 views
bottom of page